Description
CT-7001 is a selective inhibitor of CDK7.
Product Unit Size | Cost | Quantity | Stock |
---|
CT-7001 is a selective inhibitor of CDK7.
Cas No. | 1805833-75-3 |
---|---|
Purity | ≥99% |
Formula | C22H30N6O |
Formula Wt. | 394.52 |
IUPAC Name | (3R,4R)-4-[[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol |
Synonym | Samuraciclib: ICEC0942 |
Appearance | White to off white powder |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
Info Sheet |
---|
Ainscow E, Leishman A, Sullivan E, et al. Abstract 4834: CT7001: An orally bioavailable CDK7 inhibitor is a potential therapy for breast, small-cell lung and haematological cancers. Cancer Res. 2018;78(13_Supplement):4834.
Coombes C, Howell S, Krebs M, et al. Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC). Cancer Res. 2022;82(4_Supplement):GS3-10.
Constantin T, Varela-Carver A, Greenland K, et al. The CDK7 inhibitor CT7001 (samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer. 2023 Jun;128(12):2326-2337. PMID: 37036563.
Nucleoside (thymidine) analog.
Acyl-CoA synthetase inhibitor.
Endogenous neuropeptide hormone; somatostatin a...
NS3/4A inhibitor
Synthetic progestogen; PR agonist.
Endogenous peptide hormone, involved in secreti...
β-lactam; penicillin binding protein inhibitor...
p110α inhibitor.
Inhibitor of ATM.
DPP4 inhibitor.
Endogenous tachykinin peptide, involved in infl...
mTOR inhibitor.
R,R enantiomer of formoterol; β2-adrenergic an...
Potential AhR binding agent.
Macrolide; peptidyl transferase inhibitor, prot...
VEGFR1/2/3, TIE2, PDGFRβ, FGFR1, c-Kit, RET, B...
PORCN inhibitor.
Mycotoxin contaminant in food and feed.
Cyclic tetrapeptide; HDAC inhibitor.